AI assistant
Quest for Growth NV — Earnings Release 2017
Apr 3, 2017
3991_iss_2017-04-03_be5c6c6a-eb20-4232-89cc-cf8fa9c4a05b.pdf
Earnings Release
Open in viewerOpens in your device viewer
Regulated information/privileged information. This press release contains information subject to the transparency requirements imposed on listed companies.
Press release Leuven / 3 April 2017 / 8.00 AM
Schedule for publication on 3 April 2017: 8.00 AM press release available at www.questforgrowth.com
QUEST FOR GROWTH
Privak, fixed capital investment company established under Belgian Law
Leuven, 3 April 2017
Ogeda's acquisition has positive impact on net asset value Quest for Growth
Astellas Pharma announced its intention to acquire Ogeda SA (Gosselies, Belgium). Ogeda is a portfolio company of Capricorn Health‐tech Fund, in which Quest for Growth participates.
Ogeda (formerly Euroscreen) has been founded in 1994 and is focusing on discovery of small molecules targeting G‐ Protein Coupled Receptors (GPCRs). It is developing a pipeline of proprietary and partnered products. Its most advanced product is Fezolinetant. Fenzolinetant has successfully completed a phase IIa trial in hot flashes.
If the transaction is closed successfully, Quest for Growth expects a positive impact on its NAV of about € 8.6 million or € 0.57 per share. This valuation takes into account a discount on the milestone payments and on the amount that will be kept in escrow.
The announced transaction is the first significant successful divestment of Capricorn Health‐tech Fund. Earlier, in 2015, Capricorn ICT Arkiv realised the successful exit of its investment in Cartagenia. These transactions confirm that the strategy to invest indirectly in unquoted companies via Capricorn funds can have a strong positive impact on the results of Quest for Growth.
For more information we refer to the website of Ogeda ‐ www.ogeda.com
About Quest for Growth
QUEST FOR GROWTH, Privak, Undertaking for Collective Investment with fixed capital under Belgian Law. The diversified portfolio of Quest for Growth is for the most part invested in growth companies listed on European stock exchanges, in European unquoted companies and in venture capital funds. Quest for Growth focuses on innovative companies in sectors such as information‐ and communication technology (ICT), technology for life sciences (Health‐ tech) and clean technology (Cleantech). Quest for Growth has been listed on Euronext Brussels since September 23rd 1998. (www.questforgrowth.com)
For further information: Capricorn Venture Partners, asset manager of Quest for Growth Yves Vaneerdewegh, Executive Director +32 (0)16 28 41 00
QUEST FOR GROWTH NV
Privak, fixed capital investment company established under Belgian Law Lei 19 - box 3, B-3000 Leuven - Phone: +32 (0)16 28 41 28 - Fax: +32 (0)16 28 41 www.questforgrowth.com [email protected]